Brentuximab Vedotin

證據等級: L5

預測適應症: 10 個

Brentuximab Vedotin: From Hodgkin Lymphoma / sALCL to Follicular Lymphoma

One-Sentence Summary

Brentuximab vedotin (Adcetris) is a CD30-directed antibody-drug conjugate (ADC), globally approved for classical Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL), though not yet registered in the current Taiwan/US dataset. The TxGNN model predicts it may be effective for follicular lymphoma, with 6 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Classical Hodgkin lymphoma / Systemic anaplastic large cell lymphoma (global approvals; not retrieved in current dataset)
Predicted New Indication	Follicular Lymphoma
TxGNN Prediction Score	99.89%
Evidence Level	L2
US Market Status	Not retrieved (0 licenses in current dataset; likely data retrieval gap)
Number of NDAs	0
Recommended Decision	Research Question (Proceed with Guardrails)

Why is This Prediction Reasonable?

Brentuximab vedotin (BV) is an antibody-drug conjugate composed of an anti-CD30 monoclonal antibody (brentuximab) conjugated to the microtubule-disrupting cytotoxin monomethyl auristatin E (MMAE) via a protease-cleavable linker. Detailed MOA data was not retrieved in this Evidence Pack; however, the mechanism is well-characterized in the literature: upon binding to CD30-expressing tumor cells, the antibody-drug complex is internalized, MMAE is released intracellularly, and cell cycle arrest and apoptosis ensue. This mechanism is the foundation of BV’s established activity in cHL and sALCL, both of which universally or near-universally express CD30.

Follicular lymphoma (FL) is a CD20-positive indolent B-cell lymphoma. While FL cells generally express CD30 at low levels, CD30 expression is notably upregulated in transformed FL — particularly in cases undergoing transformation to ALCL (CD30+ ALK-) or other high-grade lymphomas. This creates a biologically plausible niche for CD30-targeted therapy in selected FL subpopulations, especially in the relapsed/refractory setting where transformation events are more prevalent. A published case report (PMID 32476657) documents complete response with BV in exactly this scenario: Grade I FL transformed to CD30+ ALK1− ALCL.

Multiple Phase 2 trials have been designed to explore BV in R/R FL directly — the most active being NCT04587687 (BV + bendamustine, actively recruiting, n=23). However, the pattern of other FL-targeted BV trials being withdrawn or terminated early (primarily due to recruitment difficulties) highlights that CD30-low expression in bulk FL tumors creates real-world patient selection challenges. The TxGNN score of 99.89% reflects the knowledge graph proximity between BV’s established lymphoma biology and FL’s shared lymphoid ontogeny, rather than a guarantee of broad clinical efficacy.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04587687	Phase 2	Recruiting	23	Directly tests BV + bendamustine in R/R follicular lymphoma; most representative active evidence for FL-specific BV application
NCT01805037	Phase I/II	Terminated	20	BV + rituximab as frontline therapy for CD30+ and/or EBV+ lymphomas including FL subgroup; terminated, limited data
NCT02594163	Phase 2	Terminated	25	Randomized: rituximab + bendamustine ± BV for R/R CD30+ DLBCL; partial data available despite early termination
NCT04138875	Phase 2	Withdrawn	0	Risk-stratified sequential BV-based treatment for post-transplant lymphoproliferative disorders with CD20/CD30 expression; no data
NCT02623920	Phase 2	Withdrawn	0	BV + bendamustine + rituximab in R/R CD30+ B-cell NHL; withdrawn before enrollment, no data
NCT04795869	Phase 2	Withdrawn	0	BV + pembrolizumab in recurrent systemic PTCL; not FL-specific, withdrawn with no data

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32476657	2020	Case Report	The Gulf Journal of Oncology	Complete response with BV + high-dose methotrexate in Grade I FL transformed to CD30+ ALK1− ALCL; direct proof-of-concept for BV in transformed FL
40758949	2025	Clinical Trial	Blood Advances	Phase 2 LYSA study: BV + gemcitabine in R/R PTCL (≥5% CD30+); provides BV activity benchmark in CD30-low settings relevant to FL
34797505	2022	Prospective Study	Advances in Therapy	Real-world study of BV + CEP in CD30+ NHL subtypes including TFH-phenotype PTCL; establishes BV activity in lymphomas with shared CD30 biology
35663281	2022	Review	Leukemia Research Reports	Immunotherapy in indolent NHL including FL; discusses emerging role of novel agents and CD30 targeting in FL context
38306597	2024	Review	Blood	Current treatment approaches to PTCL subtypes; BV incorporation in CD30+ frontline regimens informs biomarker selection strategy applicable to FL
39644004	2024	Review	Hematology (ASH Education Program)	Reviews BV incorporation into PTCL management and CD30 biomarker thresholds; relevant for designing FL patient selection criteria
40517441	2025	Review	Hematological Oncology	Comprehensive PTCL landscape review; positions BV in CD30+ disease and discusses cross-subtype applicability
28340875	2017	Review	Hematology/Oncology Clinics of North America	Angioimmunoblastic T-cell lymphoma review; discusses TFH-origin biology shared with FL microenvironment and BV relevance
33320379	2021	Retrospective/Case Series	European Journal of Haematology	BV + ICE in R/R PTCL; provides efficacy and safety data for BV combination strategies in relapsed CD30+ lymphoid malignancies
28967896	2018	Review	Bone Marrow Transplantation	Post-ASCT maintenance review covering BV consolidation in lymphoma including FL context; supports BV utility in maintenance settings

US Market Information

No FDA-licensed products for BRENTUXIMAB VEDOTIN were retrieved in the current dataset (0 records, query date 2026-03-24). This almost certainly reflects a data retrieval gap rather than an actual absence of US approval — brentuximab vedotin (Adcetris®, Seagen/Pfizer) holds multiple FDA-approved indications for CD30-positive lymphomas. A direct query to the FDA Orange Book or Drugs@FDA is recommended to complete this section.

Cytotoxicity

Brentuximab vedotin is an antineoplastic agent (antibody-drug conjugate; original indication is CD30+ lymphoma).

Item	Content
Cytotoxicity Classification	Targeted therapy — Antibody-Drug Conjugate (ADC); MMAE payload is a conventional cytotoxin (microtubule inhibitor, auristatin class)
Myelosuppression Risk	Moderate-to-High — neutropenia is the most common grade ≥3 adverse event; thrombocytopenia and anemia also reported
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential (each cycle), peripheral neuropathy assessment (early and ongoing), liver function tests, renal function, pulmonary symptoms monitoring
Handling Protection	Must be prepared and handled per cytotoxic drug handling regulations; MMAE is a highly potent cytotoxin requiring appropriate protective measures

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Research Question (Proceed with Guardrails)

Rationale: There is one actively recruiting Phase 2 trial (NCT04587687) directly testing BV + bendamustine in R/R FL, providing an initial evidence signal; however, the high rate of trial withdrawal and termination across other FL-targeted BV studies indicates that low CD30 expression prevalence in FL creates substantial patient selection barriers before broader clinical development is warranted.

To proceed, the following is needed:

CD30 IHC profiling of FL tumor samples (IHC ≥10% threshold): must be confirmed before patient recruitment — this is the rate-limiting step and likely explains prior trial recruitment failures
MOA data retrieval from DrugBank (DG002: High severity gap) to complete mechanistic rationale documentation
Safety data from FDA/TFDA package insert (DG001: Blocking gap) — required to initiate formal S1 safety screening
Await NCT04587687 results (Phase 2, BV + bendamustine in R/R FL, n=23, completion expected 2026-12): current trial provides the cleanest direct evidence; interim data should be reviewed before designing new studies
Epidemiological estimate of CD30+ FL prevalence: quantify the eligible patient subpopulation to assess commercial and clinical feasibility
Data linkage to transformed FL registry: the case with BV response (PMID 32476657) suggests transformed FL may be the highest-yield subpopulation; a retrospective chart review of transformed FL CD30 rates should be conducted
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.